AbbVie Inc. (FRA:4AB0)
Germany · Delayed Price · Currency is EUR | Market Cap | 450.75B +29.6% |
| Revenue (ttm) | 56.36B +10.4% |
| Net Income | 5.49B +67.7% |
| EPS | 0.29 +68.5% |
| Shares Out | n/a |
| PE Ratio | 80.70 |
| Forward PE | 18.97 |
| Dividend | 0.59 (2.50%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | n/a |
| Open | 23.80 |
| Previous Close | 23.40 |
| Day's Range | 23.80 - 23.80 |
| 52-Week Range | 16.40 - 25.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
A Worthwhile Exit Strategy
This week could mark something that hasn't happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It's all going to depend on if the share price end...
FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s
AbbVie (ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous induction regimen for Skyrizi for adults with moderately to severely active Crohn’s disease. “Patients now hav...
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the...
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after AbbVie’s (ABBV) Phase 3 INTREPID study ...
AbbVie price target raised to $294 from $258 at Goldman Sachs
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVies lutikizumab met Phase 3 endpoints in hidradenitis…
AbbVie Phase 3 Intrepid trial data ‘underwhelms,’ says RBC Capital
After AbbVie (ABBV) announced topline results from the Phase 3 INTREPID study evaluating lutikizumab in moderate to severe hidradenitis suppurativa, RBC Capital noted that the study met its primary en...
AbbVie reports ‘positive’ results from Phase 3 Intrepid trial of lutikizumab
AbbVie (ABBV) announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin 1alpha/1beta ant...
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study.
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary...
AbbVie price target raised to $294 from $258 at Goldman Sachs
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVie’s recent outperformance reflects attractive valuation, growing confiden...
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its ...
AbbVie reaches agreement with pCPA for Elahere
AbbVie (ABBV) is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance have successfully been completed for Elahere, and that a Letter of Intent has been signed by both…
AbbVie price target raised to $325 from $300 at Barclays
Barclays raised the firm’s price target on AbbVie (ABBV) to $325 from $300 and keeps an Overweight rating on the shares. The firm expects the company to report a broadly…
AbbVie, McLaren Racing announce partnership
AbbVie (ABBV) and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is...
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partn...
AbbVie reports ABBV-466 trial meets primary endpoint
AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopic remission at Week 12 than either monot...
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The trea...
AbbVie announces new, updated data from solid tumor portfolio at ESMO 2026
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO, Congress, taking place October…
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through nex...
AbbVie presents 20 scientific abstracts from its IBD portfolio
AbbVie (ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology, UEG, Week, October 17-20 in Barcelona, Spain. Key data to…
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and RI...
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
AbbVie announces presentation of 22 scientific abstracts from IBD portfolio
AbbVie (ABBV) announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease, IBD, portfolio at the American College of Gastroenterology, ACG, 2026 Annual Sci...